Toll like receptors play a role in general immunity, eye infection and inflammation : TLRs for nanodelivery
Kanwar, Jagat R., Zhou, Shu-Feng, Gurudevan, Sneha, Barrow, Colin J. and Kanwar, Rupinder K. 2011, Toll like receptors play a role in general immunity, eye infection and inflammation : TLRs for nanodelivery, Journal of clinical and cellular immunology, vol. 2, no. 4, pp. 1-10.
(Some files may be inaccessible until you login with your Deakin Research Online credentials)
Dendritic cells [DCs] are potent antigen presenting cells [APC], which plays a vital role in immune system by detecting and capturing pathogens in the body. DCs perform a pivotal role in induction of T cell response. Regulation of immune response can be achieved by specific antigen [Ag] delivery to DCs. A delivery system that can efficiently target and present Ags to DCs for the purpose of anti-tumour activity is currently a topic of significant research interest. DCs are receiving attention due to their key role in anti cancer host response and due to their adjuvanic property in tumour vaccines. Role of toll like receptors [TLR] in innate immune system and their part in eventual stimulation of adaptive immunity is exploited to develop vaccines. TLR agonists in conjugation with vaccines are shown to increase therapeutic efficacy in some cases. TLRs also play a vital role in protecting the cornea from invading pathogens. Due to adverse effects in the treatment of ocular inflammations, cancer and in viral infections, an alternate approach such as the use of TLRs will solve the inquisitive question regarding side effects. The intended delivery is attained by the use of nanoparticles which in turn leads to prolonged half-life in the body. Co-delivery of Ags, TLRs and immunomodulators using nanoparticles has been demonstrated to elicit potent cellular immune responses and are currently under development of clinically applicable immunisations and vaccines.
Reproduced with the kind permission of the copyright owner.
Field of Research
111204 Cancer Therapy (excl Chemotherapy and Radiation Therapy)
Unless expressly stated otherwise, the copyright for items in Deakin Research Online is owned by the author, with all rights reserved.
Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO.
If you believe that your rights have been infringed by this repository, please contact email@example.com.